<DOC>
	<DOCNO>NCT01881191</DOCNO>
	<brief_summary>This study evaluate effect Aubagio change brain use MRI .</brief_summary>
	<brief_title>Th Effects Aubagio Brain Pathology Multiple Sclerosis Studied Over 12 Months</brief_title>
	<detailed_description>Patients take Aubagio MRI , eye test , blood take , complete questionnaire environmental risk factor evaluate change brain disease progression . A healthy control group also complete test regimen .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>Subjects age 1865 Clinically definite MS accord Polman criterion , 52 Relapsing MS Healthy Control ( neurological disorder ) Expanded Disability Status Scale ( EDSS ) score â‰¤5.5 Disease duration &lt; 30 year Normal kidney function ( creatinine clearance &gt; 59 mL/min ) ( patient ) Signed informed consent None exclusion criterion MS patient hepatic impairment Nursing mother pregnant woman need undergo 12 month followup Women childbearing potential use reliable contraception Patients currently treat leflunomide Serum alanine aminotransferase ( ALT ) &gt; 1.5 time upper limit normal A clinically significant infectious neurological ( HC ) illness ( e.g. , cellulitis , abscess , pneumonia , septicemia ) within 30 day prior treatment assignment Unwillingness inability comply requirement protocol include presence condition ( physical , mental , social ) likely affect subject 's ability comply study protocol Any reason , opinion Investigator , indicate subject unsuitable enrollment study Other pathology relate MRI abnormality</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>multiple sclerosis</keyword>
	<keyword>relapse remit</keyword>
	<keyword>MRI</keyword>
	<keyword>teriflunomide</keyword>
	<keyword>aubagio</keyword>
	<keyword>gray matter atrophy</keyword>
	<keyword>gray matter pathology</keyword>
</DOC>